ATC Group: J05AF11 Telbivudine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of J05AF11 in the ATC hierarchy

Level Code Title
1 J Antiinfectives for systemic use
2 J05 Antivirals for systemic use
3 J05A Direct acting antivirals
4 J05AF Nucleoside and nucleotide reverse transcriptase inhibitors
5 J05AF11 Telbivudine

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Code Route Amount Notes
ORAL Oral 0.6 g

Active ingredients in J05AF11

Active Ingredient

Telbivudine is a synthetic thymidine nucleoside analogue with activity against HBV DNA polymerase. It is efficiently phosphorylated by cellular kinases to the active triphosphate form. Incorporation of telbivudine-5'-triphosphate into viral DNA causes DNA chain termination, resulting in inhibition of HBV replication.

Related product monographs

Document Type Information Source  
 SEBIVO Film-coated tablet MPI, EU: SmPC European Medicines Agency (EU)

Medicines classified under this ATC code globally

Estonia (EE)

Hong Kong (HK)

Lithuania (LT)

Poland (PL)

Romania (RO)

Singapore (SG)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.